Prostaglandin analogues of the E-series theoretically offer the ideal antiulcer drugs. Peptic ulcer healing with prostaglandin analogues is, however, no better than would be predicted from their ability to inhibit gastric acid secretion and they are less effective than histamine H2 receptor antagonists in preventing ulcer relapse. (Gut 1995; 36: 511-515) 
Abstract
Prostaglandin analogues of the E-series theoretically offer the ideal antiulcer drugs. Peptic ulcer healing with prostaglandin analogues is, however, no better than would be predicted from their ability to inhibit gastric acid secretion and they are less effective than histamine H2 receptor antagonists in preventing ulcer relapse. It could be that prostaglandin analogues inhibit gastric mucosal synthesis or release of endogenous eicosanoids, thereby abrogating their own effects. This study, therefore, examined how a single therapeutic dose (200 Kug) of misoprostol, a synthetic analogue of prostaglandin E,, influences gastric mucosal release of endogenous prostaglandin E2 (PGE2), thromboxane B2 (TXB2), and chemotactic leukotriene B4 (LTB4) during basal conditions and in response to gastric luminal acidification (0.1 M HCI; 5 mI/min for 10 minutes). Nine healthy volunteers were studied in a single blind, cross over design. In each subject misoprostol or placebo was instilled in randomised order into the stomach, which was subsequently perfused with isotonic mannitol. Misoprostol significantly decreased basal as well as acid stimulated output of PGE2 and TXB2, without affecting output of LTB4. These data show that misoprostol inhibits gastric mucosal synthesis of prostanoids. Decreased concentrations, or even a changed profile, of native eicosanoids modulating the release of inflammatory mediators from immune cells might explain why prostaglandin analogues have a comparatively poor clinical performance in ulcer healing and prevention. (Gut 1995; 36: 511-515) Keywords: misoprostol, prostaglandins, thromboxanes, leukotrienes.
Synthetic prostaglandin analogues of the Eseries, in doses recommended for ulcer healing, combine acid inhibitory effects and cytoprotective properties with an ability to inhibit meal stimulated gastrin release. -7 This triade of effects was originally considered to offer the ideal antiulcer drug. Surprisingly, prostaglandin analogues were shown to heal peptic ulcers no better than would be predicted from their ability to inhibit gastric acid secretion2 3 and in equipotent antisecretory doses they seemed equal to or even less effective than histamine H2 receptor antagonists in preventing ulcer relapse.4-6 These findings would imply that the so called cytoprotective properties of prostaglandins, shown in animal experiments8 and clinically by a significant reduction in the incidence of the gastric or duodenal ulcers associated with the use of non-steroidal anti-inflammatory drugs (NSAIDs),9 10 play no major part in ulcer healing and prevention.
Despite enormous interest in the cytoprotective phenomenon, the mechanism by which prostaglandins produce this effect is still unclear. On the other hand, a role for various inflammatory mediators in the pathogenesis of ulcer disease has been supported by both experimental models and clinical studies." 1 For example, platelet activating factor,'2 13 histamine,'4 15 and tumour necrosis factor alpha,'6-'8 in addition to leukotrienes,'3 have been implicated as mediators of gastrointestinal injury. Potent inhibitory effects of E-type prostaglandins and the prostaglandin analogue, misoprostol, on the release of proinflammatory mediators from, for example, mast cells have also been shown.'9 On theoretical grounds such effects might be beneficial in ulcer treatment and for prevention of NSAID induced gastroduodenal damage, but the administration of a synthetic prostaglandin analogue might also inhibit the synthesis or the release of endogenous eicosanoids, or both, thereby abrogating its own effects. We have, therefore, examined the acute effects of misoprostol, a synthetic analogue of prostaglandin E,, on gastric release of prostaglandin E2 (PGE2), thromboxane B2 (TXB2), and leukotriene B4 (LTB4), in addition to fluid and acid output, during 'steady state' gastric perfusions of the unstimulated and acid stimulated stomach in healthy subjects. (10 jiCi/l) as a nonabsorbable marker. Aspiration was by intermittent suction from the distal port. During the perfusion saliva was continuously removed by dental suction. After the 30 minute equilibration period 15 minute samples were collected consecutively. For acidification of the stomach 100 mM HCl plus 54 mM NaCl were infused for 10 minutes at a rate of 5 ml/min. ANALYTICAL 
PROCEDURES
The volume of the 15 minute effluents was read to the nearest millilitre. The acidity was determined by titration to pH=7-0 with 0.1 M NaOH using an autotitrator (PHM82, Radiometer, Copenhagen, Denmark The results are expressed as medians (interquartile ranges); n=9.
(<70%) and high trypsin concentrations (that is, more than 22-5 U/15 min equal to 3% of the average normal minimum trypsin output into the duodenum26). In the other nine subjects the results of recovery and trypsin determinations showed no statistically significant differences between placebo and misoprostol experiments or between basal periods and periods after luminal acidification ( Table I ).
The median recovery of gastric fluid output was 88 (78-97)% and the median value for appearance of trypsin into the stomach was 1 1 (0 7-2 1) U/15 min, which equals 0 4% of the average normal minimum trypsin output into the duodenum.
FLUID AND ACID OUTPUT
Gastric luminal acidification increased (p<001) fluid output compared with basal conditions (Table II) . Pretreatment with misoprostol reduced (p<002) basal gastric fluid output, while the acid stimulated fluid output was unchanged (p>005) compared with the corresponding placebo experiments. Misoprostol also significantly inhibited (p<002) basal gastric acid output (Table II) . LUMINAL 
OUTPUT OF PGE2
In placebo experiments basal luminal output of PGE2 was 7.4 (5.5-10-3) ng/15 min. Luminal acidification increased (p<001) basal output of PGE2 to 34.4 (18-3- (Figure) . LUMINAL 
OUTPUT OF TXB2
In placebo experiments basal luminal output of TXB2 was 9.4 (4 7-23 0) ng/15 min. After (Figure) .
LUMINAL OUTPUT OF LTB4
A considerable variability in low concentrations of LTB4 at the borderline of detection was seen. Neither luminal acidification nor misoprostol changed (p>005) luminal concentrations or output of LTB4 significantly (Figure) .
Discussion
Since the introduction of the concept of gastric mucosal protection in the early 1970s, considerable effort has been invested in exploring the mechanisms through which prostaglandins may increase the resistance of the gastrointestinal mucosa.27 While there can be little doubt that prostaglandins play a critical physiological part in maintaining the gastrointestinal mucosal integrity,l 8 11 there is no unifying concept to explain which of the numerous proposed mechanisms (for example, secretion of mucus and bicarbonate, epithelial cell proliferation and differentiation, integrity of the microcirculation) is of prime importance and any connection between cytoprotection in animal models and ulcer healing or prevention in humans remains an act of faith.5
The conflicting reports on mucosal prostaglandin formation in peptic ulcer patients probably reflect some of the difficulties inherent in the choice of an appropriate experimental design.' 8 [28] [29] [30] [31] [32] In this study luminal output of PGE2, TXB2, and LTB4, rather than the content or synthetic capacity of eicosanoids in mucosal biopsies, was measured. This was done (on the assumption that concentrations of eicosanoids in the gastric juice are reflective of mucosal concentrations) because the approach is less traumatising and minimises non-specific eicosanoid biosynthesis.33 Thus, luminal PGE2 seems to reflect the in vivo balance between mucosal synthesis and degradation, although luminal PGE2 has probably no specific function of its own.
This study was not designed to explore the possibility that mucosal prostagland in formation may be abnormal in peptic ulcer disease. Nevertheless, the results are highly relevant for the evaluation of the rationale for using prostaglandin analogues in the treatment of peptic ulcer disease and for prevention of mucosal damage associated with the use of NSAIDs. The question whether The same subjects were studied on separate days. The central line is the group median, the box encloses the middle 50% of the data values, and the tails the most extreme values within a border or 'fence' at 15 In summary, this study shows that the gastric output of PGE2 and TXB2 was significantly depressed by the prostaglandin analogue, misoprostol, while the luminal output of LTB4 was unchanged. Although our study does not identify the mechanism by which misoprostol inhibits endogenous prostanoids a tentative explanation would be that misoprostol antagonises the TXA/PG endoperoxide receptor.39 At any rate, decreased concentrations, or even a changed profile, of native eicosanoids at specific receptors of immune cells in the lamina propria might explain why prostaglandin analogues have a comparatively poor clinical performance in ulcer healing and prevention. 
